DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2vjckl/polycystic_kidney) has announced the addition of the "Global Polycystic Kidney Disease Therapeutic Pipeline Review 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Emergent BioSolutions Inc.
- Plexxikon Inc.
- Pfizer Inc.
- Synta Pharmaceuticals Corp.
- Metabolic Solutions Development Co.
- IC-MedTech, Inc.
- Endocyte, Inc.
- ManRos Therapeutics
- DiscoveryBiomed, Inc.
- Otsuka Holdings Co., Ltd.
-
Kadmon Pharmaceuticals, LLC
Drug Profiles
- tolvaptan
- lanreotide acetate
- bosutinib
- KD-020
- KD-019
- GLG-302
- MSDC-0160
- MSDC-0602
- TNFR x TWEAKR
- EC-0371
- Polycystic Kidney Disease Program
- Small Molecule to Inhibit Raf Kinase for Polycystic Kidney Disease
- STA-2842
- RCMC-30
- Small Moleucles to Activate AMPK for Polycystic Kidney Disease
- Drug For Polycstic Kidney Disease
- Drugs Targeting CIL-1 for Genetic Disorders and Polycystic Kidney Disease
- Drugs for Polycystic Kidney Disease
- Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders
- (Vitamin C + Vitamin K3)
For more information visit http://www.researchandmarkets.com/research/2vjckl/polycystic_kidney
